Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on April 9, 2025
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025
GlobeNewswire
·
April 9, 2025
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025 New Clinical Data from Phase 2 Extension Period in Ulcerative Colitis on Long-Term Benefits and Safety of Anti-IL-7R mAb Lusvertikimab NANTES, France – …
OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la “Digestive Disease Week” (DDW) 2025
GlobeNewswire
·
April 9, 2025
OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la “Digestive Disease Week” (DDW) 2025 Présentation de nouvelles données cliniques sur les bénéfices et la sécurité à long terme de l’anticorps monoclonal …
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
GlobeNewswire
·
April 9, 2025
Saint Herblain (France) and Schlieren (Zurich), April 9, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life- …
Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2
GlobeNewswire
·
April 9, 2025
Saint Herblain (France) et Schlieren (Zurich), le 9 avril 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, et LimmaTech Biologics AG, société de biotechnologies développant des vaccins pour la prévention de …
Augustine Therapeutics appoints Industry Veteran Pascale Witz as Chair of its Board of Directors
GlobeNewswire
·
April 9, 2025
New Chair brings more than three decades of life sciences industry experience, with a successful track record as a biotech company board member Significant leadership experience will be instrumental as Augustine transitions into a clinical-stage company …
The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension
GlobeNewswire
·
April 9, 2025
Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria in Black patients with confirmed resistant hypertension Allschwil, Switzerland – April 9, 2025 Idorsia Ltd (SIX …
US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement
GlobeNewswire
·
April 9, 2025
Allschwil, Switzerland – April 9, 2025 Idorsia Ltd (SIX: IDIA) today announced that the US Food …